Vasopressin V1a receptor polymorphism and interval walking training effects in middle-aged and older people

Hypertension

Volumn 55, Issue 3, 2010, Pages 747-754

  Masuki, Shizue ^a   Mori, Masayuki ^a,c   Tabara, Yasuharu ^d,f   Miki, Tetsuro ^e,f   Sakurai, Akihiro ^b   Morikawa, Mayuko ^a   Miyagawa, Ken ^a,c   Higuchi, Keiichi ^a   Nose, Hiroshi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Jukunen Taiikudaigaku Research Center   (Japan)

^d Departments of Basic Medical Research and Education   (Japan)

^e EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f EHIME UNIVERSITY   (Japan)

Author keywords

Cholesterol; Elderly; Exercise training; Hypertension; Obesity; Polymorphism; Receptors; Vasopressin

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; VASOPRESSIN V1A RECEPTOR;

ADULT; AEROBIC CAPACITY; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; LIFESTYLE; MALE; MIDDLE AGED; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRAINING; WALKING;

AGE FACTORS; AGED; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, LDL; EXERCISE; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, VASOPRESSIN; SEX CHARACTERISTICS; WALKING;

EID: 77149173476     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.147728     Document Type: Article

References (32)

1. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607-1610.
2. Nakamura K, Okamura T, Hayakawa T, Hozawa A, Kadowaki T, Murakami Y, Kita Y, Okayama A, Ueshima H. The proportion of individuals with obesity-induced hypertension among total hypertensives in a general Japanese population: NIPPON DATA80, 90. Eur J Epidemiol. 2007;22:691-698. (Pubitemid 47476681)
3. Schotte DE, Stunkard AJ. The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med. 1990;150:1701-1704.
4. Schjerve IE, Tyldum GA, Tjonna AE, Stolen T, Loennechen JP, Hansen HE, Haram PM, Heinrich G, Bye A, Najjar SM, Smith GL, Slordahl SA, Kemi OJ, Wisloff U. Both aerobic endurance and strength training programmes improve cardiovascular health in obese adults. Clin Sci (Lond). 2008;115:283-293.
5. Higashi Y, Sasaki S, Sasaki N, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. Daily aerobic exercise improves reactive hyperemia in patients with essential hypertension. Hypertension. 1999;33:591-597.
6. Walker AE, Eskurza I, Pierce GL, Gates PE, Seals DR. Modulation of vascular endothelial function by low-density lipoprotein cholesterol with aging: influence of habitual exercise. Am J Hypertens. 2009;22:250-256.
7. Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther. 2008;88:1279-1296.
8. Bray MS, Hagberg JM, Perusse L, Rankinen T, Roth SM, Wolfarth B, Bouchard C. The human gene map for performance and health-related fitness phenotypes: the 2006-2007 update. Med Sci Sports Exerc. 2009; 41:35-73.
9. Nemoto K, Gen-no H, Masuki S, Okazaki K, Nose H. Effects of high-intensity interval walking training on physical fitness and blood pressure in middle-aged and older people. Mayo Clin Proc. 2007;82:803-811.
10. Nose H, Morikawa M, Yamazaki T, Nemoto K, Okazaki K, Masuki S, Kamijo Y, Gen-No H. Beyond epidemiology: field studies and the physiology laboratory as the whole world. J Physiol. 2009;587:5569-5575.
11. Yamazaki T, Gen-No H, Kamijo Y, Okazaki K, Masuki S, Nose H. A new device to estimate VO2 during incline walking by accelerometry and barometry. Med Sci Sports Exerc. 2009;41:2213-2219.
12. Masuki S, Koshimizu T, Qian J, Higuchi K, Tsujimoto G, Nose H. Increase in respiratory quotient at night is blunted in vasopressin V1a receptor knockout mice [abstract]. J Physiol Sci. 2009;59(supp 1):221.
13. Insel TR, Young LJ. Neuropeptides and the evolution of social behavior. Curr Opin Neurobiol. 2000;10:784-789.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
15. Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome [in Japanese]. Nippon Naika Gakkai Zasshi. 2005;94:794-809.
16. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
17. Ministry of Health, Labor, and Welfare, Japan. Study Circle for Health and Nutrition Information. Recommended Dietary Allowances for Japanese. Dietary Reference Intakes [in Japanese]. 6th revision. Tokyo, Japan: Daiichi-Shuppan. 1999.
18. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148:2075-2084.
19. Kaji H, Iida K, Takahashi Y, Okimura Y, Chihara K. Hormone replacement therapy and vascular risk disorders in adult hypopituitarism. Endocr J. 2007;54:239-245.
20. Coiro V, Chiodera P. Effect of obesity and weight loss on the arginine vasopressin response to insulin-induced hypoglycaemia. Clin Endocrinol (Oxf). 1987;27:253-258. (Pubitemid 17093758)
21. Enhorning S, Leosdottir M, Wallstrom P, Gullberg B, Berglund G, Wirfalt E, Melander O. Relation between human vasopressin 1a gene variance, fat intake, and diabetes. Am J Clin Nutr. 2009;89:400-406.
22. Li JD, Burton KJ, Zhang C, Hu SB, Zhou QY. Vasopressin receptor V1a regulates circadian rhythms of locomotor activity and expression of clock-controlled genes in the suprachiasmatic nuclei. Am J Physiol Regul Integr Comp Physiol. 2009;296:R824-R830.
23. Victor RG, Shafiq MM. Sympathetic neural mechanisms in human hypertension. Curr Hypertens Rep. 2008;10:241-247.
24. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5998-6005.
25. Hart EC, Joyner MJ, Wallin BG, Johnson CP, Curry TB, Eisenach JH, Charkoudian N. Age-related differences in the sympathetic-hemodynamic balance in men. Hypertension. 2009;54:127-133.
26. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 1996:715-731.
27. Niizeki T, Takeishi Y, Takabatake N, Shibata Y, Konta T, Kato T, Kawata S, Kubota I. Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics. CircJ. 2007;71:1452-1457.
28. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K, Tasaki R, Endo F, Tanoue A. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol. 2007;21:247-258.
29. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533-2536.
30. Irving BA, Davis CK, Brock DW, Weltman JY, Swift D, Barrett EJ, Gaesser GA, Weltman A. Effect of exercise training intensity on abdominal visceral fat and body composition. Med Sci Sports Exerc. 2008;40:1863-1872.
31. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. /32-and /33-adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation. 2005;111: 3429-3434.
32. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.